Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1994 Mar;38(3):422–427. doi: 10.1128/aac.38.3.422

Activity of Bay y3118 against quinolone-susceptible and -resistant gram-negative and gram-positive bacteria.

L J Piddock 1, A J Marshall 1, Y F Jin 1
PMCID: PMC284474  PMID: 8203834

Abstract

The activity of Bay y3118 against laboratory strains of bacteria, including those with mutations in gyrA, with decreased expression of outer membrane proteins, and/or that are multiply resistant, and 121 selected clinical isolates, including highly fluoroquinolone-resistant bacteria from Spain and Argentina, was determined. Bay y3118 was extremely active (MICs, < or = 1 microgram/ml) against all bacteria, including quinolone-resistant laboratory strains. However, Bay y3118 was less active against 46 of 121 quinolone-resistant clinical isolates, such that > or = 16 micrograms of Bay y3118 per ml was required to inhibit 3 isolates. The concentration of Bay y3118 required to inhibit DNA synthesis by 50% correlated well with the MIC. Bay y3118 had accumulation kinetics similar to those of previously studied fluoroquinolones, e.g., ciprofloxacin, and there was a 50% decrease in the steady-state concentration in those members of the family Enterobacteriaceae that lacked porin proteins. Magnesium chloride at 20 mM apparently abolished the accumulation of Bay y3118 into Escherichia coli and reduced the level of accumulation into other gram-negative bacteria and Staphylococcus aureus. Carbonyl cyanide m-chlorophenylhydrazone at 100 microM enhanced the accumulation of Bay y3118 into E. coli, but it had a minimal effect on accumulation into S. aureus.

Full text

PDF
422

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alarcón T., Pita J., López-Brea M., Piddock L. J. High-level quinolone resistance amongst clinical isolates of Escherichia coli and Klebsiella pneumoniae from Spain. J Antimicrob Chemother. 1993 Oct;32(4):605–609. doi: 10.1093/jac/32.4.605. [DOI] [PubMed] [Google Scholar]
  2. Bauernfeind A. Comparative in-vitro activities of the new quinolone, Bay y 3118, and ciprofloxacin, sparfloxacin, tosufloxacin, CI-960 and CI-990. J Antimicrob Chemother. 1993 Apr;31(4):505–522. doi: 10.1093/jac/31.4.505. [DOI] [PubMed] [Google Scholar]
  3. Bremm K. D., Petersen U., Metzger K. G., Endermann R. In vitro evaluation of BAY Y3118, a new full-spectrum fluoroquinolone. Chemotherapy. 1992;38(6):376–387. doi: 10.1159/000239031. [DOI] [PubMed] [Google Scholar]
  4. Mortimer P. G., Piddock L. J. A comparison of methods used for measuring the accumulation of quinolones by Enterobacteriaceae, Pseudomonas aeruginosa and Staphylococcus aureus. J Antimicrob Chemother. 1991 Nov;28(5):639–653. doi: 10.1093/jac/28.5.639. [DOI] [PubMed] [Google Scholar]
  5. Piddock L. J., Hall M. C., Walters R. N. Phenotypic characterization of quinolone-resistant mutants of Enterobacteriaceae selected from wild type, gyrA type and multiply-resistant (marA) type strains. J Antimicrob Chemother. 1991 Aug;28(2):185–198. doi: 10.1093/jac/28.2.185. [DOI] [PubMed] [Google Scholar]
  6. Piddock L. J. New quinolones and gram-positive bacteria. Antimicrob Agents Chemother. 1994 Feb;38(2):163–169. doi: 10.1128/aac.38.2.163. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Piddock L. J., Panchal S., Norte V. Comparison of the mechanism of action and resistance of two new fluoroquinolones, rufloxacin and MF961 with those of ofloxacin and fleroxacin in gram-negative and gram-positive bacteria. J Antimicrob Chemother. 1993 Jun;31(6):855–863. doi: 10.1093/jac/31.6.855. [DOI] [PubMed] [Google Scholar]
  8. Piddock L. J., Wise R. Mechanisms of resistance to quinolones and clinical perspectives. J Antimicrob Chemother. 1989 Apr;23(4):475–480. doi: 10.1093/jac/23.4.475. [DOI] [PubMed] [Google Scholar]
  9. Piddock L. J., Zhu M. Mechanism of action of sparfloxacin against and mechanism of resistance in gram-negative and gram-positive bacteria. Antimicrob Agents Chemother. 1991 Nov;35(11):2423–2427. doi: 10.1128/aac.35.11.2423. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Sable C. A., Scheld W. M. Fluoroquinolones: how to use (but not overuse) these antibiotics. Geriatrics. 1993 Jun;48(6):41-4, 49-51. [PubMed] [Google Scholar]
  11. Schubach W. H., Whitmer J. D., Davern C. I. Genetic control of DNA initiation in Escherichia coli. J Mol Biol. 1973 Feb 25;74(2):205–221. doi: 10.1016/0022-2836(73)90107-1. [DOI] [PubMed] [Google Scholar]
  12. Walters R. N., Piddock L. J., Wise R. The effect of mutations in the SOS response on the kinetics of quinolone killing. J Antimicrob Chemother. 1989 Dec;24(6):863–873. doi: 10.1093/jac/24.6.863. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES